No headlines found.
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
Business Wire (Thu, 30-Jul 7:00 AM ET)
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
Bicycle Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol BCYC.
As of September 1, 2026, BCYC stock price declined to $4.10 with 312,968 million shares trading.
BCYC has a beta of 2.11, meaning it tends to be more sensitive to market movements. BCYC has a correlation of 0.24 to the broad based SPY ETF.
BCYC has a market cap of $286.23 million. This is considered a Small Cap stock.
Last quarter Bicycle Therapeutics PLC - American Depositary Shares reported $629,000 in Revenue and -$.72 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.19.
In the last 3 years, BCYC traded as high as $28.67 and as low as $3.75.
The top ETF exchange traded funds that BCYC belongs to (by Net Assets): IBB, BBC, SBIO, GWX, QQQS.
BCYC has underperformed the market in the last year with a return of -44.4%, while the SPY ETF gained +19.3%. In the last 3 month period, BCYC fell short of the market, returning -12.6%, while SPY returned +1.0%. However, in the most recent 2 weeks BCYC has outperformed the stock market by returning +2.5%, while SPY returned -1.4%.
BCYC support price is $4.02 and resistance is $4.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCYC shares will trade within this expected range on the day.
